These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25715243)

  • 61. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
    Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current update on cellular and molecular mechanisms of hereditary angioedema.
    Walford HH; Zuraw BL
    Ann Allergy Asthma Immunol; 2014 May; 112(5):413-8. PubMed ID: 24484972
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
    Zanichelli A; Mansi M; Periti G; Cicardi M
    Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
    MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Health-related quality of life in Danish patients with hereditary angioedema.
    Aabom A; Andersen KE; Perez-Fernández E; Caballero T; Bygum A
    Acta Derm Venereol; 2015 Feb; 95(2):225-6. PubMed ID: 24603953
    [No Abstract]   [Full Text] [Related]  

  • 66. Hereditary angioedema: Comprehensive management plans and patient support.
    Paige D; Maina N; Anderson JT
    Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S38-S42. PubMed ID: 33109325
    [TBL] [Abstract][Full Text] [Related]  

  • 67. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
    Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
    Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.
    Lumry W; Soteres D; Gower R; Jacobson KW; Li HH; Chen H; Schranz J
    Pediatr Allergy Immunol; 2015 Nov; 26(7):674-80. PubMed ID: 26171584
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema.
    Zuraw BL; Kalfus I
    Am J Med; 2012 Sep; 125(9):938.e1-7. PubMed ID: 22800873
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current treatment of hereditary angioedema: An update on clinical studies.
    Banerji A
    Allergy Asthma Proc; 2010; 31(5):398-406. PubMed ID: 20929607
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.
    Radojicic C; Riedl MA; Craig TJ; Best JM; Rosselli J; Hahn R; Banerji A
    Allergy Asthma Proc; 2021 May; 42(3):S4-S10. PubMed ID: 33980327
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes.
    Cardarelli WJ
    Am J Manag Care; 2018 Aug; 24(14 Suppl):S308-S313. PubMed ID: 30132645
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Barriers to self-administered therapy for hereditary angioedema.
    Tuong LA; Olivieri K; Craig TJ
    Allergy Asthma Proc; 2014; 35(3):250-4. PubMed ID: 24801468
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Patient's point of view].
    Raguet M
    Presse Med; 2015 Jan; 44(1):96-8. PubMed ID: 25511648
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Current state of hereditary angioedema management: a patient survey.
    Banerji A; Busse P; Christiansen SC; Li H; Lumry W; Davis-Lorton M; Bernstein JA; Frank M; Castaldo A; Long JF; Zuraw BL; Riedl M
    Allergy Asthma Proc; 2015; 36(3):213-7. PubMed ID: 25976438
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion based patient experience.
    Tachdjian R; Banerji A; Guyer A; Morphew T
    Allergy Asthma Proc; 2015; 36(2):151-9. PubMed ID: 25715244
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy.
    Zanichelli A; Arcoleo F; Barca MP; Borrelli P; Bova M; Cancian M; Cicardi M; Cillari E; De Carolis C; De Pasquale T; Del Corso I; Di Rocco PC; Guarino MD; Massaro I; Minale P; Montinaro V; Neri S; Perricone R; Pucci S; Quattrocchi P; Rossi O; Triggiani M; Zanierato G; Zoli A
    Orphanet J Rare Dis; 2015 Feb; 10():11. PubMed ID: 25758562
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of patients with angioedema without wheals: the importance of F12 gene screening.
    Firinu D; Bafunno V; Vecchione G; Barca MP; Manconi PE; Santacroce R; Margaglione M; Del Giacco SR
    Clin Immunol; 2015 Apr; 157(2):239-48. PubMed ID: 25744496
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.
    Bork K; Craig TJ; Bernstein JA; Feuersenger H; Machnig T; Staubach P
    Allergy Asthma Proc; 2015; 36(3):218-24. PubMed ID: 25803207
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Coagulation Factor XII Gene Mutation in Brazilian Families with Hereditary Angioedema with Normal C1 Inhibitor.
    Moreno AS; Valle SO; Levy S; França AT; Serpa FS; Arcuri HA; Palma MS; Campos WN; Dias MM; Ponard D; Monnier N; Lunardi J; Bork K; Silva WA; Arruda LK
    Int Arch Allergy Immunol; 2015; 166(2):114-20. PubMed ID: 25790805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.